Abstract
Oxaliplatin is a unique platinum compound with single-agent activity in both chemotherapy-naïve colorectal cancer patients and patients who progressed on 5-fluorouracil (5-FU). The combination of oxaliplatin and 5-FU has demonstrated preclinical synergy, and recent clinical trials have demonstrated enhanced activity for the combination in the clinical setting as well. UFT (uracil plus tegafur in a 4:1 molar ratio) plus oral calcium folinate (Orzel) is an oral fluoropyrimidine with several potential advantages over intravenous 5-FU and known activity in colorectal cancer. The current trial was designed to evaluate the role of these agents in combination in the treatment of patients with advanced colorectal cancer.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / pathology
-
Administration, Oral
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / pathology
-
Drug Therapy, Combination
-
Female
-
Follow-Up Studies
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / therapeutic use*
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / therapeutic use*
-
Oxaliplatin
-
Tegafur / administration & dosage
-
Tegafur / therapeutic use
-
Treatment Outcome
-
Uracil / administration & dosage
-
Uracil / therapeutic use
Substances
-
Organoplatinum Compounds
-
Oxaliplatin
-
Tegafur
-
Uracil
-
Leucovorin